Pharmacokinetics, plasma protein binding, and metabolism of a potential natural chemosensitizer from Marsdenia tenacissima in rats
| Autor: | Hui-Qin Wu, Shi-Qi Jiang, Xiao-Ling Shen, Bin Xie, Ying-Jie Hu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Paclitaxel Chemosensitizer Administration Oral Biological Availability Antineoplastic Agents Plasma protein binding Pharmacology Rats Sprague-Dawley Pharmacokinetics In vivo Liquid chromatography–mass spectrometry Tandem Mass Spectrometry Drug Discovery Animals Volume of distribution Biological Products Molecular Structure Chemistry Plant Extracts Marsdenia Metabolism Blood Proteins Bioavailability Rats Area Under Curve Injections Intravenous Microsomes Liver Adsorption Chromatography Liquid Drugs Chinese Herbal Half-Life Phytotherapy |
| Zdroj: | Journal of ethnopharmacology. 281 |
| ISSN: | 1872-7573 |
| Popis: | Ethnopharmacological relevance Marsdenia tenacissima (Roxb.) Wight et Arn is a medicinal plant mainly distributed in southwest China. It is used in folk medicine for the treatment of tumors and is synergistic with chemotherapies. In our previous study, 11α-O-2-methybutyryl-12β-O-tigloyl-tenacigenin B (MT2), a main steroid aglycone isolated from the total aglycones of M. tenacissima, significantly enhanced the in vivo antitumor effect of paclitaxel in mice bearing human tumor xenografts, showing its potential as a chemosensitizer. However, the pharmacokinetic characteristics, plasma protein binding rate, and metabolic profile of MT2 remain unclear. Aim of the study To elucidate the pharmacokinetic characteristics, plasma protein binding rate, and metabolic profile of MT2 in rats. Materials and methods MT2 in rat plasma and phosphate-buffered saline was quantified using ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method, while the MT2 metabolites in rat liver microsomes were analyzed using UPLC-triple time-of-flight MS/MS. Results For intravenously administered MT2, the maximum plasma concentration and the area under the plasma concentration-time curve indicated dose dependency, while the elimination half-life time, the mean residence time, apparent volume of distribution and total apparent clearance values remained relatively unchanged in both the 5 mg/kg and 10 mg/kg groups. For orally administered MT2, the bioavailability was 1.08–1.11%. In rat plasma, MT2 exhibited a protein binding rate of 93.84–94.96%. In rat liver microsomes, MT2 was metabolized by oxidation alone or in combination with demethylation, and five MT2 metabolites were identified. Conclusion MT2 has low oral bioavailability and a high plasma protein binding rate in rats. After administration, MT2 is transformed into oxidative metabolites in the liver. To achieve a high blood concentration of MT2, it should be administered intravenously. These findings would serve as a reference for further MT2-based pharmacological study and drug development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect